Deep intronic founder mutations identified in the ERCC4/ XPF gene are potential therapeutic targets for a high-frequency form of xeroderma pigmentosum
Chikako Senju,Yuka Nakazawa,Taichi Oso,Mayuko Shimada,Kana Kato,Michiko Matsuse,Mariko Tsujimoto,Taro Masaki,Yasushi Miyazaki,Satoshi Fukushima,Satoshi Tateishi,Atsushi Utani,Hiroyuki Murota,Katsumi Tanaka,Norisato Mitsutake,Shinichi Moriwaki,Chikako Nishigori,Tomoo Ogi
DOI: https://doi.org/10.1073/pnas.2217423120
2023-07-04
Abstract:Xeroderma pigmentosum (XP) is a genodermatosis defined by cutaneous photosensitivity with an increased risk of skin tumors because of DNA repair deficiency. The worldwide prevalence of XP is ~1 to 4 in million, with higher incidence in some countries and regions including Japan (1 in 22,000) and North Africa due to founder mutations and a high degree of consanguinity. Among XP, the complementation group F (XP-F), is a rare form (1% of worldwide XP); however, this is underdiagnosed, because the ERCC4/XPF gene is essential for fetal development and most of previously reported ERCC4/XPF pathogenic variants are hypomorphs causing relatively mild phenotypes. From the largest Japanese XP cohort study, we report 17 XP-F cases bearing two pathogenic variants, both identified in deep intronic regions of the ERCC4/XPF gene. The first variant, located in intron 1, is a Japanese founder mutation, which additionally accounts for ~10% of the entire Japanese XP cases (MAF = 0.00196), causing an aberrant pre-mRNA splicing due to a miss-binding of U1snRNA. The second mutation located in intron eight induces an alternative polyadenylation. Both mutations cause a reduction of the ERCC4/XPF gene expression, resulting in XP clinical manifestations. Most cases developed early-onset skin cancers, indicating that these variants need critical attention. We further demonstrate that antisense oligonucleotides designed for the mutations can restore the XPF protein expression and DNA repair capacity in the patients' cells. Collectively, these pathogenic variants can be potential therapeutic targets for XP.